Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Vulvar Cancer pN1b TNM Finding v8	NCIT_C139612	[Vulvar cancer with one lymph node metastasis equal to 5 mm. (from AJCC 8th Ed.)]
Vulvar Cancer pN1 TNM Finding v8	NCIT_C139610	[Vulvar cancer with regional lymph node metastasis with one or two lymph node metastases each less than 5 mm, or one lymph node metastasis equal to 5 mm. (from AJCC 8th Ed.)]
Vulvar Cancer pN2a TNM Finding v8	NCIT_C139614	[Vulvar cancer with three or more lymph node metastases each less than 5 mm. It includes micrometastasis, N2mi. (from AJCC 8th Ed.)]
Vulvar Cancer pN2b TNM Finding v8	NCIT_C139615	[Vulvar cancer with two or more lymph node metastases equal to 5 mm. (from AJCC 8th Ed.)]
Volociximab	NCIT_C48426	[A chimeric monoclonal antibody with potential antineoplastic activity. Volociximab binds to and inhibits the activity of alpha(5)beta(1) integrin, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI05)]
Larotaxel	NCIT_C48427	[A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic activities. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier.]
Taxane Compound	NCIT_C1490
Yttrium Y-90 Tacatuzumab Tetraxetan	NCIT_C48428	[A radioimmunoconjugate comprised of the humanized monoclonal antibody tacatuzumab, directed against alpha fetoprotein, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 tacatuzumab tetraxetan binds to tumor cells expressing alpha fetoprotein, thereby selectively delivering a cytotoxic dose of beta radiation.]
Yttrium Y-90 Clivatuzumab Tetraxetan	NCIT_C48429	[A radioimmunoconjugate comprised of the humanized monoclonal antibody clivatuzumab, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, thereby selectively delivering a cytotoxic dose of beta radiation.]
Vulvar Cancer pN1a TNM Finding v8	NCIT_C139611	[Vulvar cancer with regional lymph node metastasis with one or two lymph node metastases each less than 5 mm. It includes micrometastasis, N1mi. (from AJCC 8th Ed.)]
Mango Flavor	NCIT_C73400	[A characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles mango.]
Structured Product Labeling Flavor	NCIT_C73338	[A characteristic of a medicinal product, specifying the most predominant flavor. Flavor is not an FDA specification for the names of specific flavors that may appear as inactive product ingredients in labeling.]
Tilt	NCIT_C48433	[The degree of deviation from a vertical plane.]
Meat Flavor	NCIT_C73402	[A characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles meat.]
X-Ray Tube	NCIT_C48435	[A vacuum tube containing a metal target onto which a beam of electrons is directed at high energy for the generation of X rays.]
Menthol Flavor	NCIT_C73403	[A characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles menthol.]
Kilo	NCIT_C48436	[A prefix indicating a quantity of one thousand, 10E3.]
Zibotentan	NCIT_C48430	[An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to the ET-A receptor, thereby inhibiting endothelin-mediated mechanisms that promote tumor cell proliferation.]
Endothelin Receptor Antagonist	NCIT_C28313	[A group of agents that bind to endothelin receptors, thereby inhibiting the actions of endothelins. Inhibition of endothelins may decrease tumor growth, progression, and angiogenesis. (NCI04)]
Neural Crest-Derived Cell	NCIT_C48431